Neridronate Sodium
Neridronate sodium was approved on Jan 1, 2002 in Italy. It was developed and marketed as Nerixia® by Abiogen in Italy.
Neridronate is a new amino bisphosphonate. It is indicated to treat osteogenesis imperfecta and paget's disease of bone.
Nerixia® is available as injection solution for intravenous use, containing 25 or 100 mg of Neridronate sodium. The indicative posology is of 2 mg/kg body weight every 3 months.
General Information
Update Date：2015-09-07
- Drug Name：
- Neridronate Sodium
- Research Code：
- Trade Name：
- Nerixia®
- MOA：
- Bisphosphonate
- Indication：
- Osteogenesis imperfecta; Paget's disease
- Status：
- Approved
- Company：
- Abiogen (Originator)
- Sales：
- ATC Code：
- M05BA
Approved Countries or Area
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2002-01-01 | Marketing approval | Nerixia | Osteogenesis imperfecta,Paget's disease | Injection, Solution | 25 mg/100 mg | Abiogen |
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 299.13 | ||||||||||||
| Formula | C6H16NO7P2 • Na | |||||||||||||
| CAS No. |
79778-41-9 (Neridronic Acid); 80729-79-9 (Neridronate Sodium); |
|||||||||||||
| Chemical Name | 6-Amino-1-hydroxy-1,1-hexanediphosphonic Acid Monosodium Salt | |||||||||||||
| Neridronic Acid （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2015-10-09
